AlphaRose Therapeutics, a preclinical-stage biotechnology company dedicated to developing and commercializing treatments for neurogenetic developmental disorders, today announced its acquisition of Alpha Anomeric SA, a French biotech specializing in a proprietary oligonucleotide chemistry platform known as abcDNA. AlphaRose is currently advancing its lead antisense oligonucleotide candidate, Rosiphersen, through IND-enabling studies, with plans to initiate clinical trials in early 2026. The novel gene control platform under development at AlphaRose is expected to be strengthened by the integration of Alpha Anomeric’s abcDNA technology. Financial details of the transaction were not disclosed.

Founded to commercialize a novel oligonucleotide chemistry platform invented at the University of Bern (Switzerland) by Professor Christian Leumann and Dr. Damien Evoquez, Alpha Anomeric was established by Dr. Wolfgang Renner in partnership with lead investor Advent Life Sciences. The company has demonstrated the broad applicability of the abcDNA platform to oligonucleotide-based therapeutics, designed to improve safety, efficacy, and therapeutic versatility across multiple disease areas.

Alpha Anomeric will continue to operate as a subsidiary of AlphaRose, headquartered in Paris, France. In addition to acquiring innovative technology, this transaction establishes a European footprint for AlphaRose, bolstering its strategic plans for global commercialization, including expansion throughout Europe.

We are excited to welcome Alpha Anomeric into the AlphaRose family and to unlock the full potential of their groundbreaking technology, said Casey McPherson, Founder and CEO of AlphaRose. Our focus on oligonucleotide therapies for neurogenetic and rare genetic disorders makes abcDNA an ideal complement to our platform, positioning AlphaRose as a leader in this field.

Dr. Wolfgang Renner, Founder and former CEO of Alpha Anomeric, added, We are pleased that AlphaRose recognizes the promise of our technology. We look forward to seeing abcDNA further developed within their therapeutic programs.

Alan Walts, Executive Chairman of AlphaRose, remarked, We appreciate the contributions of the Alpha Anomeric team, Advent Life Sciences, and the University of Bern in advancing the abcDNA platform. We are eager to integrate this technology into AlphaRose and to make it available to other companies pursuing next-generation oligonucleotide therapies.

Source: https://www.prnewswire.com/news-releases/alpharose-therapeutics-announces-acquisition-of-alpha-anomeric-sa-a-french-company-with-industry-leading-oligonucleotide-technology-302440678.html